Outlook Therapeutics Inc (OTLK) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Outlook Therapeutics Inc   (NASDAQ: OTLK)


Outlook Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Outlook Therapeutics Inc 's ROA in the third quarter of 2026?
Outlook Therapeutics Inc recorded a cumulative net loss of $-61 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -282.89%.

However, within the Healthcare sector 882 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4559, from total ROA ranking in the second quarter of 2026 at 5344.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
III. Quarter		 (Mar 31 2026)
II. Quarter		 (Dec 31 2025)
I. Quarter		 (Sep 30 2025)
IV. Quarter		 (Jun 30 2025)
III. Quarter
Y / Y Total Assets Change 15.41 % 17.23 % -34.93 % -34.93 % -52.53 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -61 -61 -103 -62 -43
Return On Assets (TTM) -282.89 % -294.01 % -516.59 % -278.02 % -173.79 %
OTLK's Total Ranking # 4559 # 5344 # 4682 # 4646 # 70
Total Assets (TTM) in million 26 22 19 19 23
Seq. Total Assets Change 17.1 % 18.05 % 0 % -16.52 % 18.94 %
Seq. Net Income Change - - - - -

OTLK's 5 Years Annual ROA >> Back to OTLK Management Effectiveness >> Compare OTLK ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 135
Sector # 883
Overall # 4505

Return On Assets Statistics
High Average Low
68.23 %
-196.68 %
-523.23 %
(Mar 31 2025)   (Dec 31 2025)



  News about Outlook Therapeutics Inc Return on Assets ROA

Leadership Change at Outlook Therapeutics: Navigating Challenges Amidst Regulatory Milestones

In a notable shift within its leadership, Outlook Therapeutics Inc. has appointed Faisal G. Sukhtian as Chairman of the Board of Directors as of January 31, 2025. Sukhtian steps into the role formerly held by Randy Thurman, who will continue to support the company as Lead Independent Director. This transition comes at a pivotal time for Outlook Therapeutics, a biopharmaceutical firm that recently celebrated a significant milestone with the European Union and the United Kingdom granting regulatory approval for the first authorized use of an ophthalmic formulation of bevacizumab, specifically designed to treat wet age-related macular degeneration (wet AMD).Despite this promising development, Outlook Therapeutics faces a challenging financial landscape. As of the end of 2024, the company recorded a cumulative net loss of $75 million, reflecting the high costs associated with research, development, and regulatory compliance in the competitive healthcare sector. Such losses translate to a staggering negative return on assets (ROA) of -189.73%. For context, this performance positions Outlook Therapeutics well below the industry average, with 867 other companies within the healthcare sector reporting higher returns on assets.



Financial Statements
Outlook Therapeutics Inc 's Assets $ 26 million OTLK's Balance sheet
Outlook Therapeutics Inc 's Income $ -20 million Quarterly OTLK's Income Statement
OTLK's Income by Division See OTLK's Income by Division



Annual Return On Assets (Sep 30 2025)
FY 2025		 (Sep 30 2024)
FY 2024		 (Sep 30 2023)
FY 2023		 (Sep 30 2022)
FY 2022		 (Sep 30 2021)
FY 2021
Y / Y Total Assets Change -34.93 % -12.04 % 12.85 % 28.56 % 15.6 %
Total Assets in million 19 29 33 29 23
Y / Y Net Income Change - - - - -
Net Income in million -62 -75 -59 -66 -53
Annual Return On Assets -329.57 % -258.91 % -178.22 % -225.24 % -233.06 %

OTLK's 5 Years Annual ROA >> Back to OTLK Management Effectiveness >> Compare OTLK ROA to its Competitors



More Return On Assets Ratios
OTLK's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OTLK's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OTLK's Competitors
Subscribers only: Roa for Outlook Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for OTLK's Customers

You may also want to know
OTLK's Roi OTLK's Inventory Turnover Ratio OTLK's Growth Rates OTLK's Dividend Comparisons
OTLK's Profitability Ratios OTLK's Asset Turnover Ratio OTLK's Dividend Growth
OTLK's Roe OTLK's Valuation Ratios OTLK's Financial Strength Ratios OTLK's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-08-29T17:35:54+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.